Associations between metabolic disorders and risk of cancer in Danish men and women - a nationwide cohort study

被引:13
作者
Berger, Siv Mari [1 ]
Gislason, Gunnar [1 ,5 ,6 ]
Moore, Lynn L. [3 ]
Andersson, Charlotte [1 ]
Torp-Pedersen, Christian [2 ]
Denis, Gerald V. [3 ,4 ]
Schmiegelow, Michelle Dalgas [1 ]
机构
[1] Herlev & Gentofte Univ Hosp, Dept Cardiol, Hjertemedicinsk Forskning 1,Post 635, DK-2900 Copenhagen, Denmark
[2] Aalborg Univ, Dept Hlth Sci & Technol, Aalborg, Denmark
[3] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA
[4] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA
[5] Univ Southern Denmark, Natl Inst Publ Hlth, Copenhagen, Denmark
[6] Danish Heart Fdn, Copenhagen, Denmark
关键词
Cancer; Metabolic; Diabetes; Hypertension; Hypercholesterolemia; Epidemiology; BODY-MASS INDEX; LONG-TERM USE; CARDIOVASCULAR-DISEASE; RECEPTOR BLOCKERS; OBESITY; METAANALYSIS; POPULATION; PREVALENCE; OVERWEIGHT; INHIBITORS;
D O I
10.1186/s12885-016-2122-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The prevalence of metabolic disorders is increasing and has been suggested to increase cancer risk, but the relation between metabolic disorders and risk of cancer is unclear, especially in young adults. We investigated the associations between diabetes, hypertension, and hypercholesterolemia on risk of all-site as well as site-specific cancers. Methods: We consecutively included men and women from nationwide Danish registries 1996-2011, if age 20-89 and without cancer prior to date of entry. We followed them throughout 2012. Metabolic disorders were defined using discharge diagnosis codes and claimed prescriptions. We used time-dependent sex-stratified Poisson regression models adjusted for age and calendar year to assess associations between metabolic disorders, and risk of all-site and site-specific cancer (no metabolic disorders as reference). Results: Over a mean follow-up of 12.6 (+/- 5.7 standard deviations [SD]) years, 4,826,142 individuals (50.2 % women) with a mean age of 41.4 (+/- 18.9 SD) years had 423,942 incident cancers. Incidence rate ratios (IRRs) of all-site cancer in patients with diabetes or hypertension were highest immediately following diagnosis of metabolic disorder. In women, cancer risk associated with diabetes continued to decline albeit remained significant (IRRs of 1.18-1.22 in years 1-8 following diagnosis). For diabetes in men, and hypertension, IRRs stabilized and remained significantly increased after about one year with IRRs of 1.10-1.13 in men for diabetes, and 1.07-1.14 for hypertension in both sexes. Conversely, no association was observed between hypercholesterolemia (treatment with statins) and cancer risk. The association between hypertension and cancer risk was strongest in young adults aged 20-34 and decreased with advancing age. Conclusions: Diabetes and hypertension were associated with increased risk of all-site cancer.
引用
收藏
页数:10
相关论文
共 50 条
[1]   CANCER RISK IN PATIENTS WITH DIABETES-MELLITUS [J].
ADAMI, HO ;
MCLAUGHLIN, J ;
EKBOM, A ;
BERNE, C ;
SILVERMAN, D ;
HACKER, D ;
PERSSON, I .
CANCER CAUSES & CONTROL, 1991, 2 (05) :307-314
[2]   Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people [J].
Andersson, Charlotte ;
Vaag, Allan ;
Selmer, Christian ;
Schmiegelow, Michelle ;
Sorensen, Rikke ;
Lindhardsen, Jesper ;
Gislason, Gunnar H. ;
Kober, Lars ;
Torp-Pedersen, Christian .
BMJ OPEN, 2012, 2 (03)
[3]   A review of global cancer burden: Trends, challenges, strategies, and a role for surgeons [J].
Are, Chandrakanth ;
Rajaram, Shireen ;
Are, Madhuri ;
Raj, Hemanth ;
Anderson, Benjamin O. ;
Swamy, Ramesh Chaluvarya ;
Vijayakumar, Manavalan ;
Song, Tianqiang ;
Pandey, Manoj ;
Edney, James A. ;
Cazap, Eduardo L. .
JOURNAL OF SURGICAL ONCOLOGY, 2013, 107 (02) :221-226
[4]   Long-term use of antihypertensive drugs and risk of cancer [J].
Assimes, Themistocles L. ;
Elstein, Eleanor ;
Langleben, Adrian ;
Suissa, Samy .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (11) :1039-1049
[5]   BET domain co-regulators in obesity, inflammation and cancer [J].
Belkina, Anna C. ;
Denis, Gerald V. .
NATURE REVIEWS CANCER, 2012, 12 (07) :465-477
[6]   Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium [J].
Bosetti, C. ;
Rosato, V. ;
Li, D. ;
Silverman, D. ;
Petersen, G. M. ;
Bracci, P. M. ;
Neale, R. E. ;
Muscat, J. ;
Anderson, K. ;
Gallinger, S. ;
Olson, S. H. ;
Miller, A. B. ;
Bueno-de-Mesquita, H. Bas ;
Scelo, G. ;
Janout, V. ;
Holcatova, I. ;
Lagiou, P. ;
Serraino, D. ;
Lucenteforte, E. ;
Fabianova, E. ;
Ghadirian, P. ;
Baghurst, P. A. ;
Zatonski, W. ;
Foretova, L. ;
Fontham, E. ;
Bamlet, W. R. ;
Holly, E. A. ;
Negri, E. ;
Hassan, M. ;
Prizment, A. ;
Cotterchio, M. ;
Cleary, S. ;
Kurtz, R. C. ;
Maisonneuve, P. ;
Trichopoulos, D. ;
Polesel, J. ;
Duell, E. J. ;
Boffetta, P. ;
La Vecchia, C. .
ANNALS OF ONCOLOGY, 2014, 25 (10) :2065-2072
[7]   Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults [J].
Calle, EE ;
Rodriguez, C ;
Walker-Thurmond, K ;
Thun, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (17) :1625-1638
[8]   Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms [J].
Calle, EE ;
Kaaks, R .
NATURE REVIEWS CANCER, 2004, 4 (08) :579-591
[9]   Prevalence, Metabolic Features, and Prognosis of Metabolically Healthy Obese Italian Individuals The Cremona Study [J].
Calori, Giliola ;
Lattuada, Guido ;
Piemonti, Lorenzo ;
Garancini, Maria Paola ;
Ragogna, Francesca ;
Villa, Marco ;
Mannino, Salvatore ;
Crosignani, Paolo ;
Bosi, Emanuele ;
Luzi, Livio ;
Ruotolo, Giacomo ;
Perseghin, Gianluca .
DIABETES CARE, 2011, 34 (01) :210-215
[10]   Cancer occurrence in Danish diabetic patients: duration and insulin effects [J].
Carstensen, B. ;
Witte, D. R. ;
Friis, S. .
DIABETOLOGIA, 2012, 55 (04) :948-958